RE: The next steps26 Apr 2020 15:11
Worth posting again!
From yesterday by M.McNulty - thank you!
"A strong close to the week yesterday. I really expect the share price to push up into the 150-200p range in the coming days and weeks.
The only two hurdles remaining are: Cytiva announcing whether they have successfully put the Affimer reagent on its device, and whether testing has demonstrated that it is sensitive and specific enough for commercialisation.
In my opinion, the chances of success are very high:
- The company has already stated that its newly generated Affimers bind to SARS-CoV-2 with extremely high specificity;
- I highly doubt Cytiva would have attached their name to this project, were they not very confident that the tech transfer was a simple process (it is after all very well-trodden), and that efficacy of Affimers would not be diminished on their strips;
- Two academic reports have been published in recent weeks about saliva being a reliable tool to detect SARS-CoV-2.
If/when these two hurdles are cleared, then the sky is the limit for Avacta’s share price, for me.
The only major (known) potential for bad news would be the initial readouts for the impending pro-dox trial, which we should hear about early next year. And so we'd have a good six months of just positive news about more partnerships - and crucially, sales - in the Diagnostics division (i.e. COVID1-19 tests).
Until those hurdles are cleared, the share price will be driven by:
- more partnerships secured with major diagnostics companies, to produce lateral flow devices and perhaps high throughput immunoassays (like PCR testing);
- pre-orders of test strips by bodies such as PHE;
- grant funding.
Then of course there is always the potential for updates on partnerships (existing or new), within the Therapeutics division. There should also be news on the Company's in-house pipeline of products-under-development, notably an IND/CTA submission for pro-dox.
Investment thesis, 01/03/2020:
aimchaos.files.wordpress.com/2020/03/avacta-group-investment-thesis-3.pdf
Update note, 15/04/2020:
aimchaos.files.wordpress.com/2020/04/avacta-group-update.pdf
Please could everyone stop responding to, or even commenting on, trolls. They will only become increasingly frequent in the weeks ahead, unfortunately, as the share price rises. There will always be envy and bitterness in the world. By referring to their presence in any way at all, you are assisting them in clogging this board and distracting existing and potential new investors from actual discussion on the Company and sharing of research. Please don’t even respond to this last paragraph. Just use the filter button liberally."
Sign In
Follow the stocks
